Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Dividend Appreciation Index Fund ETF (VIG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Vanguard Dividend Appreciation Index Fund ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Dividend Appreciation Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Dividend Appreciation Index Fund ETF trades at $246.45, while Zimmer Biomet Holdings Inc trades at $96.37 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.

VIGZBH
52-Week High
$245.79$107.71
52-Week Low
$208.67$79.58
Market Cap
$18.55B
Sector
Health
Enterprise Value
$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Dividend Appreciation Index Fund ETF

VIG trades at $246.06, up 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on dividend growth, with a 1.5% yield and a 20-year streak of dividend increases. Recent news highlights its appeal for long-term income investors, with top holdings like Broadcom driving performance. Support and resistance are tightly clustered around $245–$247.

Outlook remains positive for dividend growth investors, with low expense ratios and quality stock selection. Risks include interest rate sensitivity and market volatility. Analyst sentiment is favorable, emphasizing defensive positioning and long-term wealth building.

Zimmer Biomet Holdings Inc

ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.

The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Dividend Appreciation Index Fund ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VIG

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH